1 Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 2 transmission identifies community social distancing as the dominant 3 intervention reducing outbreaks

4 **AUTHORS**

5 Luke B Snell 1, 2

6 Chloe L Fisher 3

7 Usman Taj 2

8 Blair Merrick 1, 2

9 Adela Alcolea-Medina 5

10 Themoula Charalampous 1

11 Adrian W Signell 4

12 Harry D Wilson 4

13 Gilberto Betancor 4

14 Mark Tan Kia Ik 1

15 Emma Cunningham 5

16 Penelope R Cliff 5

17 Suzanne Pickering 4

18 Rui Pedro Galao 4

19 Rahul Batra 1, 2

20 Stuart J D Neil 4

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 Michael H Malim 4

22 Katie J Doores 4

23 Sam T Douthwaite 2

24 Gaia Nebbia 1, 2

25 Jonathan D Edgeworth^ 1, 2

26 Ali R Awan^ 3

27 & The COVID-19 Genomics UK (COG-UK) consortium* 6

28

29 ^These authors are joint corresponding authors.

30 *Full list of consortium names and affiliations are in the appendix.

31

32 **AFFILIATIONS**

33 1 Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, School of
34 Immunology and Microbial Sciences, King's College London

35 2 Directorate of Infection, Guy's and St Thomas' NHS Foundation Trust

36 3 Genomics Innovation Unit, Guy's and St. Thomas' NHS Foundation Trust

37 4 Department of Infectious Diseases, King's College London

38 5 Infection Sciences, Viapath, St Thomas' Hospital, London

39 6 <https://www.cogconsortium.uk>

40

41

42

43 **FUNDING**

44 This work was supported by the King's Together Multi and Interdisciplinary Research Scheme (Wellcome Trust
45 Revenue Retention Award, and the National Institute for Health Research (NIHR) Biomedical Research Centre
46 programme of Infection and Immunity (RJ112/N027) based at Guy's and St Thomas' National Health Service
47 (NHS) Foundation Trust and King's College London.

48

49 COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation
50 (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the
51 Wellcome Sanger Institute.

52 **ETHICS**

53 Favourable opinion to conduct this work was granted by the North West Preston Research Ethics Committee
54 (Reference 18/NW/0584)

55 The COVID-19 Genomics UK (COG-UK) consortium study protocol was approved by the Public Health
56 England Research Ethics and Governance Group (reference: R&D NR0195).

57

58 ABSTRACT

59 Many healthcare facilities report SARS-CoV-2 outbreaks but transmission analysis is complicated by the high
60 prevalence of infection and limited viral genetic diversity. The contribution of different vectors to nosocomial
61 infection or the effectiveness of interventions is therefore currently unclear. Detailed epidemiological and viral
62 nanopore sequence data were analysed from 574 consecutive patients with a PCR positive SARS-CoV-2 test
63 between March 13th and March 31st, when the pandemic first impacted on a large, multisite healthcare
64 institution in London. During this time the first major preventative interventions were introduced, including
65 progressive community social distancing (CSD) policies leading to mandatory national lockdown, exclusion of
66 hospital visitors, and introduction of universal surgical facemask-use by healthcare-workers (HCW). Incidence
67 of nosocomial cases, community SARS-CoV-2 cases and infection in a cohort of 228 HCWs followed the same
68 dynamic course, decreasing shortly after introduction of CSD measures and prior to the main hospital-based
69 interventions. We investigated clusters involving nosocomial cases based on overlapping ward-stays during
70 the 14-day incubation period and SARS-CoV-2 genome sequence similarity. Our method placed 63 (79%) of
71 80 sequenced probable and definite nosocomial cases into 14 clusters containing a median of 4 patients (min
72 2, max 19). No genetic support was found for the majority of epidemiological clusters (31/44, 70%) and
73 genomics revealed multiple contemporaneous outbreaks within single epidemiological clusters. We included
74 a measure of hospital enrichment compared to community cases to increase confidence in our clusters, which
75 were 1-14 fold enriched. Applying genomics, we could provide a robust estimate of the incubation period for
76 nosocomial transmission, with a median lower bound and upper bound of 6 and 9 days respectively. Six (43%)
77 clusters spanned multiple wards, with evidence of cryptic transmission, and community-onset cases could not
78 be identified in more than half the clusters, particularly on the elective hospital site, implicating HCW as vectors
79 of transmission. Taken together these findings suggest that CSD had the dominant impact on reducing
80 nosocomial transmission by reducing HCW infection.

81

82 INTRODUCTION

83 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in
84 December 2019 (1), since when over 40 million infections and 1 million deaths have been reported worldwide
85 (2). New cases in the UK peaked during the first wave after implementation of progressive community social
86 distancing (CSD) (3), starting with an announcement on March 16th that, with few exceptions, the whole UK
87 population must stay at home, later being made mandatory on March 23rd. COVID-19 hospital admission then
88 peaked around 8 days later (4).

89 The first few weeks of the pandemic were unique, due to introduction of SARS-CoV-2 into populations without
90 prior immunity. Society and healthcare organisations were adapting to the pandemic for the first time with
91 frequent new infection control policies and behavioural changes while incidence was still accelerating. During
92 the first wave, elective hospital admissions were often postponed (5). Currently, hospitals around the world
93 either have, or are preparing for, a further influx of COVID-19 patients, while restarting and rescheduling
94 postponed non-COVID-19 work. It is therefore important to identify evidence from these first few weeks to help
95 healthcare organisations efficiently plan for any subsequent increase in cases.

96 Most COVID-19 transmission studies to date have utilised epidemiological analysis alone to identify outbreaks,
97 including those from the UK (6) (7), China (8), France (9) and South Korea (10). The main limitation with using
98 epidemiology alone is that when point prevalence is high, for instance at 2.2% in London during the first wave
99 in April 2020 (11), this increases the chance two people in epidemiological contact are independent cases.
100 Furthermore, a wide incubation period of between 2 and 14 days (12,13) makes it difficult to define hospital-
101 onset cases as hospital-acquired, as even when they arise several days after admission to hospital the
102 transmission event may still have occurred in the community.

103 To improve the confidence in detecting hospital clusters, epidemiological analysis can be supplemented with
104 genomic data obtained by sequencing viral isolates. For COVID-19, thus far only two published studies have
105 used genomic sequencing to analyse hospital transmission (14) (15). However, application of genomic data
106 to the spread of SARS-CoV-2 is not straightforward, particularly as during early stages of the pandemic, genetic
107 diversity was low with less than 200 mutations registered in the international GISAID database by April 2020
108 (16). SARS-CoV-2 also has a low mutation rate with only 2-3 mutations per genome per month (17). These
109 factors increase the chance that two people infected with virus sharing identical genetic sequence are not
110 closely epidemiologically linked cases. However, epidemiological linkage combined with viral sequence data

111 can provide stronger evidence for a COVID-19 transmission cluster than would be possible with either source
112 of data alone.

113 Nosocomial infection is reported to account for around 10-20% of all confirmed cases (18) (19) (6) (20) often
114 in designated outbreaks (6) (7) (8) (9) (10) and with a crude death rate of up to 30% (19). The most likely
115 routes of transmission are between patients and involving healthcare workers (HCW) , with potential for all
116 combinations of directionality to occur within the same nosocomial cluster. In each case, the transmitting
117 individual may be either symptomatic or asymptomatic. There is also potential for super-spreading events (21).
118 It is important to determine the contribution of each pathway to help prioritise resourcing of interventions. Most
119 hospitals excluded visitors, who are an alternate source for introducing infection, and although the environment
120 can become contaminated with infectious droplets, cleaning policies effectively removes virus from the
121 environment (22), so fomite spread remains an unproven mode of transmission (23). Airborne transmission
122 via aerosols remains controversial (23).

123 The aim of this study was to develop a methodology for combining epidemiological and genomics analysis of
124 SARS-CoV-2 transmission to help determine the pathways for nosocomial transmission during the first wave
125 of the pandemic. During this time there was a high incidence in the community (11) and high incidence of
126 COVID-19 infection amongst healthcare workers (HCWs) as judged by subsequent seroconversion (24) (25).

127

128 RESULTS

129 Setting, clinical characteristics and epidemiology of cases in the first wave of the pandemic

130 SARS-CoV-2 PCR testing for all hospital admissions and inpatients with compatible clinical symptoms of new
 131 fever or cough was commenced on March 13th in line with national UK recommendations. Between 80 and
 132 150 SARS-CoV-2 PCR tests were performed per day until the end of April when testing increased further
 133 (Table S1), with 637 positive tests on 574 individuals up until March 31st. The majority of positive cases were
 134 admitted to hospital (483/574, 84%, Table S4), consistent with national recommendations to only test those
 135 requiring hospital treatment. Cases detected on admission to hospital had a median reported symptom history
 136 of 7 days (interquartile range IQR 3-10, available for 385/483, 80%, of cases; Table S4).

137 New positive cases increased rapidly to a peak between March 31st and April 8th, before falling steadily
 138 through to the end of April (Figure 1). The number of daily new combined probable and definite nosocomial
 139 cases initially increased in line with community diagnoses, but peaked a week earlier than hospital SARS-CoV-
 140 2 admissions on March 23rd to a maximum of 12 new cases per day. Nosocomial cases then rapidly declined
 141 to low levels of 0-2 cases a day during April (Figure 1) and none in the following 4 months (data not shown).
 142 When the symptom onset date for community cases admitted to hospital is considered, the peak of symptom
 143 onset for community and nosocomial cases overlap (Supplemental Figure 1).

144 462 (80%) of the 574 SARS-CoV-2 positive patients were categorised based on NHS England and ECDC
 145 definitions (26) as community-onset, with 63 (11%) definite nosocomial, 27 (5%) probable nosocomial and 22
 146 (4%) indeterminate cases (see Methods). Demographics of each group are shown in Table 1. 323 (56%) were
 147 male and the median age was 61, although indeterminate, probable nosocomial, and definite nosocomial
 148 cases were older (73 years for each group) than community cases (58 years). 225 (49%) of the 455 patients
 149 having ethnicity recorded were of black and minority ethnicities (BAME). This proportion was higher amongst
 150 community cases (201/371, 54%), compared to indeterminate (6/12, 50%), probable (5/20, 25%) and definite
 151 nosocomial cases (13/52, 25%). Comorbidity was lower in community-onset cases 89 compared to probable
 152 and definite nosocomial cases (median Charlson score 2 (IQR 0-5) versus 5 (IQR 4-6) respectively). The
 153 overall crude in-hospital mortality was 20%, ranging from 17% for community-onset cases to 37% for definite
 154 nosocomial cases. Of the 574 cases diagnosed until March 31st, 541 were within the study period for genomic
 155 analysis between March 13th and 31st. SARS-CoV-2 genome sequence was obtained from 370 of 541 (68%)
 156 cases, including 89% (80/90) of all probable and definite nosocomial cases and 72% (168/234) of cases placed
 157 into epidemiological clusters (Table S4, S7).

158 **Healthcare worker symptomatology and sero-conversion**

159 The cumulative number of HCWs reporting COVID-19 compatible symptoms and having documented
 160 seroconversion from a cohort of 228 HCWs is shown in Figure 1. 43/228 (19%) seroconverted to SARS-CoV-
 161 2 IgG, with 44% (19/43) having done so by their first follow-up (April 10th) and 95% (41/43) by May 1st (Table
 162 S2). Of note 13/43 (30%) were asymptomatic. Figure 1 presents the predicted period of peak HCW
 163 infectiousness based on a combination of ± 2 days from date of symptom onset (n=30) or seroconversion
 164 data where symptoms were not present (n=13). The rapid rise in HCW infection is predicted to have been
 165 between March 16th and 25th overlapping with similar rapid rises in community cases reported elsewhere (3),
 166 and both symptom reporting by our community-onset cases and incidence of nosocomial cases.

167 **Linking epidemiology and genomics to define transmission clusters**

168 Strict epidemiological criteria were used to place patients into clusters based on having at least one overlapping
 169 time-point in the same ward, outpatient setting, care home or dialysis facility during 14 days prior to their
 170 positive sample (Figure 2a). Each cluster had to include a nosocomial case. This identified 44 epidemiological
 171 clusters involving 234 cases comprising 123 community admissions, 89 nosocomial acquisitions (62 definite,
 172 27 probable) and 22 indeterminate cases, with a median of 6 patients per cluster (range 2 - 21) (Table S6;
 173 Figure 2c for clusters 4-33). Viral genomic haplotype information for each case was then used to resolve the
 174 44 epidemiological clusters to create 'combined' final epidemiological and genetic clusters. In combined
 175 clusters the majority of all patient haplotypes must be identical, and no patient's viral haplotype can differ from
 176 the main cluster haplotype by more than 1 SNP (Figure 2a). This process resulted in 14 combined
 177 epidemiological and genetic clusters (Figure 2b, d). The combined clusters were then mapped onto the original
 178 44 clusters constructed from epidemiological data alone (Figure 2c, Table S8), where each patient in an
 179 epidemiological cluster is classified as either belonging to a combined cluster (coloured bar), or having a
 180 haplotype that was not in any combined cluster (grey) or without viral sequence (black).

181 In this manner, 31/44 (70%) epidemiological clusters, including some of the largest, did not have genetic
 182 support as they did not have even two cases belonging to any combined cluster (Figure 2c, Table S7). 13/44
 183 (30%) included at least one case from two or more combined clusters, indicating cases from multiple
 184 contemporaneous outbreaks harboured within an epidemiological cluster (Figure 2c, Table S7).

185 **Cluster spatial distribution and enrichment**

186 Of the 14 combined epidemiological and genetic clusters, 5 were on the acute admitting hospital site, 7 were

on the elective hospital site and two at intermediate care facilities. These 14 clusters contained 63/80 (79%) of all sequenced probable and definite nosocomial cases (Figure 2d). 3/5 (60%) clusters on the acute site (STH) included a community-onset or indeterminate case, which plausibly served as the originator of SARS-CoV-2 outbreak. This contrasts with the 9 clusters on elective and intermediate sites, which by policy did not knowingly admit COVID-19 patients, where only three (3/9, 33%) included a community-onset or indeterminate case that could have plausibly originated the outbreak (Figure 2d; Supplemental Figure 2 for ward movements). The validity of creating these final 14 clusters was supported by comparing their lineage enrichment compared to community sequences reported to COG-UK consortium CLIMB database during the study period (27). Clusters were enriched by between 1 (for the smallest clusters) and 14-fold (median 4-fold) (Figure 2d, Table S7). In terms of spatial distribution, 7/12 hospital clusters were contained within single wards, 3 clusters were spread on two wards (in 2 cases this involved adjacent wards), and 2 clusters were spread across more than two wards (Figure 4).

Unsequenced community-onset cases are unlikely to be originators of clusters

We assessed the likelihood that unsequenced community-onset cases may have served as the originator of clusters, where no community-onset or indeterminate cases could be found, by reviewing cases epidemiologically linked with nosocomial clusters. We excluded cases as potential originators if i) they were diagnosed after the first nosocomial case, or ii) available sequence did not meet cluster inclusion criteria (i.e differed from main cluster viral haplotype by >1 SNP), or iii) if they were not community-onset or indeterminate cases (Table S11). Of all the clusters without originators, only 2 clusters could have potentially been originated by an unsequenced community-onset case with epidemiological linkage (case 50 or case 187 for GUY4; case 62 for GUY5).

Deducing Transmission Networks and Estimating Incubation Period

Patient movements, timing of positive SARS-CoV-2 test, viral haplotype data and SNP acquisition were combined and analysed to infer the place and time period of SARS-CoV-2 acquisition, and predict the direction of transmission from donor to recipient. This analysis could be applied to 5 hospital clusters comprising 24 patients (Figure 5, Supplemental Figure S 3A-D, Table S9 and S10) with patients assigned a lower bound (n=12) and/or upper bound (n=23) for acquisition of SARS-CoV-2, and hence their incubation period (Figure 5a,b,c). The aggregate analyses gave a median lower bound of 6 days and median upper bound of 9 days (Figure 5d, Supplemental Figure 3 A-D, Table S10), consistent with estimates that range from 2-14 days with a median estimate of 5-7 days (28).

217 Representation of healthcare workers in transmission networks

218 HCW were required to self isolate immediately upon developing COVID-19 compatible symptoms and were
 219 not routinely offered SARS-CoV-2 RNA testing. For this reason there are only 20 SARS-CoV-2 sequences
 220 from HCW in the dataset. 17 did not share genomic similarity with other cases, which excludes them from
 221 contributing to transmission within sequenced clusters. The viral haplotypes from 3 HCW shared genetic
 222 similarity with cluster cases, 1 of which (case 280) cared for a nosocomial case (case 60) within cluster STH1
 223 and shared the same haplotype. Case 280 therefore can be added to cluster STH1, however 280 is unlikely
 224 to be the originator of this cluster as they were diagnosed more than 7 days after the first case in this cluster.

225

226

227 DISCUSSION

228 This combined epidemiological and genomic analysis spans 19 days of intense community transmission in
 229 London during the first wave of the pandemic, which coincided with the main period of nosocomial
 230 transmission, comprising 90 definite or probable nosocomial cases across our healthcare institution. This was
 231 also the period when stepwise increases in public health restrictions were introduced, including repeated
 232 instructions to stay at home and socially distance by at least 2 metres in public places from 16th March, through
 233 to national lockdown on March 23rd.

234 Our transmission analysis during this important period provides evidence informing methodological
 235 approaches to nosocomial SARS-CoV-2 outbreak detection. First, both epidemiological and genomic
 236 information is essential for accurate linkage of nosocomial cases into putative SARS-CoV-2 clusters: we could
 237 not find genomic support for over half of the transmission clusters discovered using epidemiological data alone,
 238 and the rest are significantly reduced in size (Fig 3c, Table S7, S8). This latter point is illustrated by
 239 epidemiological cluster 8, where genome sequence identified the presence of 3 genomic clusters within a
 240 single epidemiologically defined cluster. Second, we show that isolates with a single SNP difference can
 241 reasonably be included within clusters given the known SARS-CoV-2 mutation rate and the timeframe of
 242 nosocomial transmission clusters. These single SNPs were highly informative as they helped determine the
 243 sequence of transmission (Figure 5, Supplemental Figure 3 A-D). Third, it is important to assess the likelihood
 244 that linked nosocomial cases even with identical genomes might be due to chance due to the high prevalence
 245 of that sequence in the community. We included a method to assess enrichment compared with the
 246 surrounding London population by comparing data from the COG-UK CLIMB database, which showed cluster
 247 enrichment ranging from 1 to 14 fold. Importantly, the lowest enrichment was seen for clusters of size 2 (Figure
 248 2d). For cases where the enrichment is over 1, this approach gives greater confidence in the definition of
 249 clusters and is an important measure that has not thus far been used in other genetic studies. Fourth, we show
 250 that for SARS-CoV-2, given its relatively long incubation time, patients should be considered in clusters based
 251 on contact during previous admissions. Five patients across 3 clusters (case 520, 362, 236 in STH1, 278 in
 252 STH3 and 277 in GUY1, see Supplementary Figure 1) had epidemiological contact during a previous
 253 admission to the one during which they were diagnosed. Such contact is not currently considered in published
 254 definitions. Finally, we were also able to robustly estimate median incubation period for nosocomial cases as
 255 between 6-9 days, which, to our knowledge, is the first time the COVID-19 incubation period has been
 256 estimated using both genetics and epidemiological data. This is consistent with published evidence that most
 257 people become symptomatic within 7 days of exposure (13). In addition, our study showed a similar proportion

258 of probable and definite nosocomial cases could be placed into transmission clusters. Thus when a probable
259 nosocomial case is found it is likely to be a genuine nosocomial case and should be treated as such.

260 A number of clusters (GUY1, GUY2, GUY4, GUY5) involved cryptic transmission across multiple wards which
261 is consistent with untested individuals such as staff or asymptomatic patients, but not patient visitors, as
262 missing links in transmission clusters. For instance, clusters GUY1 and GUY2 involved 4 wards, with an
263 identical viral haplotype circulating with high enrichment compared to the community. Whilst these two clusters
264 meet our cluster definition as defined in Methods, they are not merged due to there being no patient overlap
265 in ward stay between the clusters. Given these were highly enriched clusters, in the same building just a few
266 floors apart, and with no community-onset case as the originator of GUY2, the most parsimonious explanation
267 is cryptic transmission between the two. Similarly in GUY1 there is no patient who clearly could have infected
268 case #551 (see Supplementary Figure 1). Lastly, GUY4 and GUY5 involve highly enriched haplotypes across
269 neighbouring wards. These situations suggest cryptic transmission, and 'missing links' which may be HCW or
270 asymptomatic, untested patients.

271 With the above methodological approaches defined, we focussed on the initial period of nosocomial SARS-
272 CoV-2 transmission to try and identify factors explaining its rapid rise and fall. There was initially a complete
273 temporal overlap between the increase in community cases, healthcare worker symptoms, and incidence of
274 nosocomial cases. We propose that the most likely explanation is that HCWs were an essential contributor to
275 the intensity of nosocomial transmission during this initial period, potentially by both initiating and sustaining
276 transmission. This is supported by a number of findings. First, reported symptoms in HCW with confirmed
277 infection were before or at the time of lockdown on 23rd March, with their peak infectivity predicted to coincide
278 with peak nosocomial transmission (Figure 1). Second, cryptic transmission between wards was clearly
279 demonstrated, suggesting involvement of untested individuals moving between wards, with HCWs being the
280 most likely vector. Third, we were unable to identify community or indeterminate cases who may have served
281 as originators for more than half of clusters, suggesting involvement of untested individuals such as HCW.
282 Indeed many clusters also occurred on the elective sites, where cases were not knowingly admitted. Finally,
283 we did link 1 of only 20 tested HCWs to a transmission cluster, which although not the originator, is consistent
284 with the potential for HCWs to sustain outbreaks. Whilst HCW seem the most likely source of transmission it
285 is however possible that unrecognised patient-to-patient transmission occurred, for instance by asymptomatic
286 patients or in areas where we do not have epidemiological data, such as radiology departments

287 Subsequently, from around March 16th, progressive CSD rapidly reduced community SARS-CoV-2

transmission, which would also decrease the incidence of HCWs infected in the community, lowering their potential to contribute to nosocomial transmission. Consistent with this conclusion, nosocomial infection fell rapidly from March 23rd to the end of the study in line with reported community infections, and before any potential impact from surgical mask use or banning of visitors to hospital.

It is harder to interpret events after 31st March. It is notable that SARS-CoV-2 patients continued to be admitted, peaking on 8th April, whilst nosocomial cases fell and remained low. One conclusion is that admission of community-onset cases is in itself unlikely to cause large clusters. Partly this may be due to rapid diagnosis of clinically suspected cases and pre-emptive isolation, in an environment where HCWs are wearing appropriate PPE. Additionally, It may be that by the time community-onset cases of SARS-CoV-2 are admitted to hospital (in our study a median day 7 days post onset of symptoms) they are less infectious because viral load is falling. Indeed, this is consistent with previous studies showing a median duration of viral shedding of 4 days post onset of symptoms (29).

In summary, this study supports routine use of genome sequencing for SARS-CoV-2 outbreak investigation and provides a framework for data interpretation that calls into question continued reliance on using epidemiology alone. A multi-site clinical trial, COG-UK HOCl, is currently investigating whether provision of real-time sequencing for outbreak analysis can help infection control teams interrupt transmission (30). We provide data supporting a conclusion that HCWs infected in the community are a major contributor to nosocomial transmission during the initial stage of the first wave of the pandemic, which was halted by implementation of CSD policies. With community transmission returning, including to HCWs, there will be an opportunity to assess whether nosocomial transmission returns to the same intensity with policies such as universal mask use in place, or whether additional interventions such as regular staff testing or rapid SARS-CoV-2 genome sequencing is required to limit nosocomial transmission. This is particularly important given the challenges re-introducing CSD policies and the need to continue with non-COVID-19 clinical activity.

313 METHODS

314 Setting

315 Guy's and St Thomas' Hospital NHS Foundation Trust includes: 1) an acute admitting adult hospital site with
 316 an Emergency Department (St Thomas') also hosting the network lead centre for nationally-commissioned
 317 respiratory high consequence infectious diseases (HCID), which admitted some of the first UK SARS-CoV-2
 318 cases to specialised intensive care and general wards. It was also the only site knowingly admitting COVID-
 319 19 patients. 2) an elective ambulatory site including elective orthopaedic and thoracic surgery, a cancer centre,
 320 dialysis and renal transplant unit (Guy's); 3) two long stay community care units and 4) multiple community
 321 dialysis units. All sites are part of the same management structure and were part of a single operational
 322 pandemic response structure with daily meetings throughout and received the same laboratory diagnostic and
 323 infection control services. Infection control policies were reviewed daily with reference to frequent updates from
 324 Public Health England and NHS England, to implement stepwise measured derogation of Personal Protective
 325 Equipment (PPE) use while caring for known and suspected COVID-19 patients moving from HCID designation
 326 to caring for hundreds of COVID-19 patients. Hospital visitors and relatives were excluded from the hospital
 327 from March 25th, and universal HCW surgical mask use policy was introduced for all patient interactions across
 328 all hospital and community facilities on March 28th.

329

330 Sample retrieval and clinical data collection

331 490 surplus RNA extracts from SARS-CoV-2 combined nose and throat swabs collected between 13th and
 332 31st March 2020 inclusive, predominantly from patients within the catchment South East London boroughs,
 333 and stored in the routine diagnostic laboratory after completion of all clinically-requested tests, were retrieved
 334 by the primary care team. Swabs had been tested using multiplexed tandem PCR (AusDiagnostics two-step
 335 multiplexed-tandem (MT-PCR) Coronavirus Typing Eight-well Panel; cat. no. 2061901) targeting ORF1a of
 336 SARS-CoV-2. 448 extracts had been reported as SARS-CoV2 detected and 42 not-detected. The cycle
 337 threshold (Ct) value was taken as 15 plus the diagnostic MT-PCR take off value. Isolates with a Ct of 16 – 37
 338 were regarded as eligible for WGS. Extracts were anonymised and linked with a limited set of clinical data
 339 (Table 1) and the admission and ward stay dates by the primary care team, before submission to the research
 340 team. Favourable opinion to conduct this work was granted by the North West Preston Research Ethics
 341 Committee (Reference 18/NW/0584).

342

343 Anonymisation

344 All patients and samples were anonymised using a unique patient and sample identification number. Ward
345 stays were anonymised using the following schema: locations beginning with 'A' represent ambulatory or
346 outpatient locations numbered A01 to A60; if prefixed with 'ED' represent emergency departments; if starting
347 with 'IC' represent an intensive care unit; each patients usual residence was named 'Home' followed by their
348 anonymised patient ID, and inpatient wards were anonymised using three letter international airport codes.

349

350 COVID-19 Whole Genome Sequencing

351 SARS-CoV-2 positive RNA isolates were processed as described in pcr-tiling-ncov-
352 PTC_9096_v109_revF_06Feb2020-gridion from Oxford Nanopore Technologies (ONT) with V3 PCR primers
353 from the ARTIC protocol (31). 24 samples were prepared in each library. 3µl of synthesised cDNA was used
354 in each PCR reaction instead of the ONT suggested 2.5µl and 35 PCR cycles were conducted. The 20°C
355 incubation was extended to 10 minutes in the end-prep step. All the AMPure XP bead clean-up steps used a
356 1:1 ratio of library to AMPureXP beads. The post-barcode ligation bead clean-up was washed with 2x 450µl
357 SFB washes rather than the ONT suggested 700µl. 17.5ng of the final library was loaded onto the flow cell for
358 sequencing. The flow cell sequenced for 3 days or until there were very few active pores remaining.

359 Generation of SARS-CoV-2 consensus sequence and variant and lineage calling from raw Nanopore reads

360 From raw Nanopore reads, COVID-19 viral consensus sequences and variants were generated using the Artic
361 bioinformatic pipeline v 1.0 as described in Artic Network(32) . Lineages were assigned using the Pangolin
362 software (33) version 1.1.14 with lineages version 2020-05-19.

363 Haplotype construction for patients

364 For each patient, a viral haplotype was constructed by juxtaposing all variants from the .pass.vcf file output by
365 the Artic bioinformatics pipeline above. The exception was for genomic positions that were known to be
366 homoplastic according to problematic sites ([https://raw.githubusercontent.com/W-L/ProblematicSites_SARS-](https://raw.githubusercontent.com/W-L/ProblematicSites_SARS-CoV-2/master/problematic_sites_sarsCov2.vcf)
367 [CoV-2/master/problematic_sites_sarsCov2.vcf](https://raw.githubusercontent.com/W-L/ProblematicSites_SARS-CoV-2/master/problematic_sites_sarsCov2.vcf)) . These sites at positions 635, 11074, 11083, 16887, 21575,
368 were all masked and not included in any haplotypes.

For patient 363, three variants (C3096T, G13627T, C15540T) were also taken from the .fail.vcf file. This patient was in a transmission cluster with strong epidemiological evidence linking them to 4 patients who all had variants C3096T, G13627T, and C15540T. All three of these variants were found in all of the other patients in this transmission cluster. This situation with variants in the .fail.vcf file rather than the .pass.vcf file only arose for patient 363 in our dataset.

Definitions and deduction of transmission Clusters

Transmission clusters were deduced in a series of stages using combined epidemiological and genetic information, in three phases as follows. First, each patient sample was placed in nosocomial categories based on date of testing according to NHS England and ECDC definitions (26): Community (<3 days from admission), indeterminate (3-7 days from admission), probable Nosocomial (8-14 days from admission) and definite nosocomial (>14 days from admission). Epidemiological clusters were constructed using the following rules (Fig 2a and table S7): At least two cases in the epidemiologically defined cluster; at least one probable or definite nosocomial case; all cases in the seed cluster must overlap with at least one other patient in the same seed cluster. Overlap was defined as both patients being on the same ward at the same time for at least one day during the incubation period set as 14 days prior to the positive SARS-CoV-2 positive swab (13).

In the second phase of cluster construction, genetic information was added by considering the viral haplotype for each patient in the epidemiological cluster. Epidemiological clusters were split into combined epidemiological + genetic clusters where every patient has the same viral haplotype. These combined epidemiological plus genetic clusters are termed “seed” clusters.

In the third phase, additional patients were added to seed clusters based on the following criteria: the patient added must overlap with at least one patient in the seed cluster (where overlap is defined as above); the added patient has a viral haplotype that differs only one SNP from the seed cluster viral haplotype. Patients who met criterion 1 (overlap) but whose viral haplotypes differed by 2 SNPs from the seed cluster viral haplotype were added to the cluster if at least one of the “missing” SNP positions was called as an N due to insufficient sequence coverage in consensus sequence generation. For two clusters, (STH4, STH5) phase 3 involved merging two different seed clusters whose viral haplotypes differed from each other by one SNP.

There are two clusters that are exceptions to the above rules: GUY3 and GUY4. These two clusters were added upon manual inspection of the combined epidemiological and genetic data. In both cases, two patients whose viral haplotype differed by a single SNP overlapped on the same ward during their incubation period,

and a third patient, whose viral haplotype was identical to that of one of the two previously mentioned patients was present on an adjacent ward at the same time, also during their incubation period. These two clusters violate the criterion given above that seed clusters should be on a single ward, but are nonetheless considered as transmission clusters because the two wards (Samaritan and Hedley Atkins) in both cases are spatially adjacent and with frequent sharing of staff across wards, especially at night..These clusters also showed high enrichment compared to community haplotypes (see below.)

Calculation of Hospital compared with Community Enrichment for cluster viral haplotypes

Enrichment of viral haplotype frequencies amongst nosocomial and community cases were calculated as follows (Table S8 and Fig 2). For a given haplotype, the hospital frequency (H) was calculated by dividing the number of patients in the dataset by the total number of sequenced patients in our dataset (370). COG-UK consortium data in COV_GLUE was extracted on 29th June 2020 to assess community haplotype frequencies (27). To assist with SQL queries, a view from several tables was created with the following SQL query:

```
"create table full as select m.id as sequence_id,m.collection_date as
collection_date,adm0,adm1,adm2,num_ns,longest_n_run,num_unique_snps,pang_lineage,cov_glue_lineag
e,cov_nt_mutation_id as mut_id from cov_coguk_metadata m join cov_sequence s join
cov_cov_nt_mutation_sequence ms on m.id = sequence_id and ms.sequence_sequence_id = sequence_id ;"
```

Two numbers were used to calculate the community frequency,: the entire community population of relevance, and the number of patients with the given haplotype in the community population. The community population (Cd) was defined as all the sequenced patients within the study period (13th to 31st March inclusive) with a location of 'GREATER LONDON', 'LONDON', or 'CITY OF LONDON', whichever had greater than 90% sequence coverage (952 people). This number was obtained using the following SQL query:

```
"select count(distinct sequence_id) from full where (adm2 like '%LONDON%' and adm2 != 'LONDONDERRY')
and (collection_date >= '2020-03-13' and collection_date <= '2020-03-31') and num_ns/29401 < 10;"
```

Where 29401 is the length of the reference viral genome coding region, so given the percentage of Ns in the sequenced sample. Requiring a cutoff of less than 10% Ns is equivalent to greater than 90% sequencing coverage, which is the cutoff required for our samples in this study.

The number of patients with the given haplotype in the community population was calculated by determining the number of sequences in the community population that had all of the SNP variants in the given haplotype,

426 and no more. For this purpose, any homoplastic SNPs that had been removed from consideration when
 427 constructing patient viral haplotypes within our study population (see section “*Haplotype construction for*
 428 *patients*” above), namely SNPs at positions 635, 11074, 11083, 16887, 21575, were added back to calculate
 429 the haplotype numbers in the community, as these SNPs had not been removed in the samples submitted to
 430 COG-UK. The following is an example query to obtain the number of patients in the community with the
 431 haplotype for our cluster STH1 (C241T,C3037T,C14408T,A23403G,C25350T):

432 “select distinct sequence_id from full where 100*(num_Ns/29903) < 10 and sequence_id in (select
 433 sequence_id from full where collection_date >= '2020-03-13' and collection_date <= '2020-03-31' and mut_id
 434 = 'C3037T') and sequence_id in (select sequence_id from full where collection_date >= '2020-03-13' and
 435 collection_date <= '2020-03-31' and mut_id = 'C14408T') and sequence_id in (select sequence_id from full
 436 where collection_date >= '2020-03-13' and collection_date <= '2020-03-31' and mut_id = 'A23403G') and
 437 sequence_id in (select sequence_id from full where collection_date >= '2020-03-13' and collection_date <=
 438 '2020-03-31' and mut_id = 'C25350T') and (adm2 like '%LONDON%' and adm2 != 'LONDONDERRY') group
 439 by sequence_id having count(distinct mut_id) = 4”

440 Results were obtained for 11 community sequences where community frequency was defined as C_n / C_d . A
 441 correction factor of 1 was then added to C_n as a pseudocount to avoid dividing by zero for cases where $C_n =$
 442 0. Thus the formula for community frequency is $(C_n + 1) / C_d$ and the formula to calculate nosocomial
 443 enrichment for a given haplotype was $H / [(C_n + 1) / C_d]$.

444 Healthcare worker (HCW) serology and symptom reporting

445 Blood sample collection to determine COVID-19 seroconversion was offered to consenting healthcare workers
 446 at Guy’s & St Thomas’ Hospital after expedited approval from the Trust’s R&D office, occupational health and
 447 medical director ((34)). Sequential serum samples were collected approximately every 1-2 weeks from 228
 448 HCWs between 13th March and 10th June 2020. Samples were tested using a published ELISA assay with
 449 sera diluted 1:50 considered positive if they gave an OD for IgG against both N and S that was 4-fold above
 450 the negative control sera. Self-reported COVID-19 related symptoms were recorded by participants and days
 451 post onset of symptoms in seropositive individuals was determined using this information. For asymptomatic
 452 seropositive individuals, days POS was defined as the first timepoint SARS-CoV-2 Abs were detected. Six
 453 HCWs had a confirmed SARS-CoV-2 PCR+ infection. Serology results were communicated individually to
 454 HCWs and collectively to the hospital as part of preparation for universal HCW serology testing that
 455 commenced in May 2020.

456 **FIGURE and TABLE LEGENDS**

457 **FIGURE 1** Epidemiological description of cases diagnosed during the first wave. On the left hand y-axis , the
 458 grey bar chart displays new cases over time between March 10th and April 31st. Over the same period the
 459 right hand y axis shows incidence of nosocomial cases (orange line) and, the proportion (%) of screened HCW
 460 with confirmed infection reporting symptom onset (black line) with peak period of infectivity ± 2 days (dashed
 461 black line), with IgG seroprevalence of HCW (green). Overlaid is 5 key dates in public policy and infection
 462 control (A) March 13th; testing recommended for all inpatients with cough and fever. (B) March 16th; strong
 463 government advice for social distancing; (C) March 23rd; implementation of national lockdown (D) March 25th;
 464 exclusion of hospital visitors (E) March 28th; mandatory use of surgical masks for all patient interactions under
 465 2 metres.

466

467 **FIGURE 2a)** i) Potential incubation period for a patient is defined as the time from 14 days prior to sample
 468 collection up to sample collection.

469 ii) An overlap between two patients (circles with numbers indicating different patients) is defined as two patients
 470 who stay on the same ward at the same time, both during their potential incubation period (red circles). The
 471 following scenarios are not considered to be overlap: one patient is not in their potential incubation period (grey
 472 circle); two potentially incubating patients are on two different wards at the same time; two potentially
 473 incubating patients are on the same ward at two non-overlapping times (i.e. different days).

474 iii) An epidemiological (epi) cluster is defined as a set of overlapping patients based on ward stays, where
 475 overlap is defined as above, and every patient in the set overlaps at least one other patient in the set, and at
 476 least one patient in the set is nosocomial (in hospital >7 days before tested for COVID-19 after having shown
 477 symptoms). When viral haplotypes information is taken into account for the patients in a single epi cluster,
 478 there are two possible results. In scenario 1, the epi cluster is decomposed into several epi + genetic clusters
 479 (indicated by non-red colours) where different colours mean different haplotypes, and a star indicates that a
 480 patient has a single additional genetic variant (at most) in addition to the variants comprising the coloured
 481 haplotype. In scenario 2, the addition of genetic information decomposes the single epidemiological cluster
 482 into individual patients with unique haplotypes, not clustering by genomics.

483 iv) Individual epidemiological plus genomics clusters from different wards are merged if they share at least one
 484 patient, and every patient in the resulting merged cluster has at most one SNP difference from the main cluster

485 haplotype.

486 **FIGURE 2b)** Haplotype representations of the fourteen clusters that emerge after applying the process
 487 depicted in part a) to epidemiological and viral genetic data (see Methods). Clusters are named after the
 488 hospital site they occur in (leftmost column). Cluster haplotype lineages are shown in black (second column
 489 from left). Cluster haplotypes are depicted (rightmost column) with a “1” in a given position indicating the
 490 presence of the SNP relative to the reference genome shown above in vertical text, and a “.” indicating its
 491 absence (wild-type sequence). Cluster rows are coloured based loosely on the similarity of the cluster
 492 haplotypes to one another. This same colour scheme is used to represent specific clusters in subsequent
 493 figures.

494 **FIGURE 2c)** Epidemiological clusters 4-33, including cases where $n > 2$ (Table S7) are coloured according to
 495 how many of their patients belong to a combined epidemiological plus genomics cluster, with the colour
 496 indicative of the viral haplotype (Figure 2b). Patients with viral haplotypes not found in any combined cluster
 497 are coloured grey, and those patients for which sequence was unavailable are shown in black. Epidemiological
 498 cluster number is shown on the x-axis. Epidemiological cluster 1 -3 are not displayed due to their large size.

499 **FIGURE 2d)** Combined epidemiological plus genomic clusters from the acute and elective hospital sites.
 500 Clusters are coloured according to viral genomic haplotype (Figure 2b). Clusters are shown broken down into
 501 PHE patient nosocomial categories, with different shapes indicating the different categories. Enrichment of the
 502 cluster viral haplotype frequency in our study dataset vs. the frequency in the community (Table S8, Methods)
 503 is shown on top of each cluster column.

504

505 **FIGURE 3** - Pictorial representation of ward stays and movements for patients within cluster GUY1. Each row
 506 represents a different case. Patient ID, designation, lineage and SNP variants are marked. Ward movements
 507 between March 1st to 31st are displayed. Different wards are by given colours. Where there is >1 ward stay
 508 on one day, the longest ward stay is represented. The sample collection date is marked with an ‘x’. Time
 509 periods outside of the acquisition period are shaded.

510

511 **FIGURE 4)** 3D spatial representation of St. Thomas’ Hospital **(a)** and Guy’s Hospital **(b)** is shown with wards
 512 where transmission of clusters STH1-5 and GUY1-7 occurred (Table S10) are coloured according to viral

513 genetic haplotype (Figure 2b). The numbers in the ward indicate the number of patients from the given cluster
514 inside that ward during their incubation period (as defined in Figure 2a).

515

516 **FIGURE 5a)** Patient movement diagram and inferred transmission network for cluster STH3. Patient
517 movements from home to hospital and between wards within St. Thomas' Hospital are shown from the 8th to
518 the 25th of March. Shapes indicate the nosocomial designation assigned to the patient as in Figure 2 (d).
519 Patients are coloured according to viral haplotype (Figure 2b) from the earliest date at which it can be deduced
520 that they could have caught COVID-19 onwards, based on the viral haplotype and the movement of other
521 patients within the cluster. Prior to the inferred earliest possible infection start date they are shown as white
522 shapes. Double-sided arrows indicate a patient staying on a ward for several days. Patients 16 and 29 originate
523 the cluster, arriving from home sites within 1km of each other on the 8th and 9th, into Ward A (LON), where
524 they transmit the same viral haplotype to patients 90 and 144. Patient 90 is then moved to Ward B (INV) on
525 the 11th, which leads to the infection of patients 230 and 319, and in the process an accumulation of an extra
526 SNP in the viral haplotype (pink asterisk, A11781G). Patient 278 is infected with this new viral haplotype
527 sometime between the 16th and 18th, when they are on ward B. Patient 278 went back and forth between
528 home and the hospital several times, so while strictly designated as "Community", likely caught this rare
529 hospital-enriched SARS-CoV-2 haplotype in Ward B.

530

531 **FIGURE 5b)** Inferred transmission network. The most parsimonious COVID-19 transmission network for this
532 cluster based on patient ward movements and viral haplotypes is shown. The pink asterisk indicates the
533 mutation of the original haplotype via the acquisition of an additional SNP A11781G.

534 **FIGURE 5c)** Inferred lower and upper incubation period bounds for selected patients from cluster STH4. Based
535 on the patient ward movements (part a) and the transmission network (part b), the lower and upper bounds of
536 when certain patients must have contracted SARS-CoV-2 are indicated by coloured squares, with days prior
537 to SARS-CoV-2 test (indicated with an "X") shown as negative integers.

538 **FIGURE 5d)** Aggregate boxplots of lower and upper bounds for incubation period for all patients for which the
539 types of deduction shown in parts c) are possible, for all combined epi + genetic clusters STH1-5, GUY1-7
540 (Figure S2, Table S11). The number of patients for which the lower bound or upper bound inference was
541 possible is indicated above each boxplot. The median number of days is indicated inside the boxplot for the

542 lower bound and the upper bound for the incubation period.

543

544 **TABLE 1** Demographics of the 574 cases diagnosed by the diagnostic lab until March 31st, separated by
545 community-onset, indeterminate, probable nosocomial, and definite nosocomial infections.

546

547 **SUPPLEMENTAL TABLE LEGENDS**

548 **SUPPLEMENTAL FIGURE 1** Epidemiological description of cases diagnosed during the first wave. On the left
549 hand y-axis, the grey bar chart displays cumulative symptom onset for admitted cases where symptom onset
550 is known, between March 10th and April 31st. Over the same period the right hand y axis shows incidence of
551 nosocomial cases (orange line) and, the proportion of screened HCW with confirmed infection reporting
552 symptom onset (olive line), and IgG seroprevalence of HCW (green).

553

554 **SUPPLEMENTAL FIGURE 2** Ward movement diagrams for the combined clusters formed through
555 epidemiological and genetic analysis. Each row represents one patient's movements. Lineage, nosocomial
556 designation and haplotype are shown. Ward stays are shown coloured by different ward location, with time on
557 the horizontal axis. Where a patient is on two wards in one day, the ward with the longest stay is represented.
558 An 'x' marks date of specimen collection for the first positive PCR test for SARS-CoV-2 for each patient.

559 **SUPPLEMENTAL FIGURES 3A - 3D** Patient movement and transmission network analogous to figure 5 a-c
560 for clusters STH1 (Figure S 3A), STH4 (Figure S 3B), GUY1 (Figure S 3C), and GUY3 (Figure S 3D). Patient
561 shapes are as specified for Figure 5. Colours are for cluster-specific viral haplotypes, as specified in Figure
562 2b. Ward names are independent for each cluster (so "Ward A" on Figure S 3A is not necessarily the same as
563 "Ward A" on Figure S 3B).

564 **SUPPLEMENTAL FIGURE 3A** Patient 127 is the likely origin of the part of cluster STH1 that is on Ward A
565 (KUL ward from Table S5, Table S8). Patient 127 arrives from home to the ward where the nosocomial patients
566 are infected (Ward A) within a two day period. Nosocomial patients 245, 206, 354, 293, and 480 are infected
567 in Ward A after the arrival of patient 127 onto Ward A having already been on this ward before patient 127
568 arrives (245,480, 293, 206) or arriving after patient 127 (354). Patients 245, 480, 293, and 206 are then

569 transferred to Ward C (SFO), which sets a lower bound on when they must have been infected (as they were
570 infected in Ward A). Subsequently nosocomial patient 469 is infected on Ward C. Independently, patient 127
571 is moved to Ward B (DEL), where patient 268 gets infected.

572 **SUPPLEMENTAL FIGURE 3B** Two transmission scenarios (i and ii) are considered for cluster STH4. Either
573 patient 212 arrives on Ward A already a carrier, which leads to the infection of nosocomial patients 337, 396,
574 351, and 374 (scenario “i”), or the viral haplotype was already circulating on Ward A (DEN) prior to the arrival
575 of patient 212 (scenario “ii”). In scenario (i), patient 212 transmits the virus to one of patients 337, 396, or 351,
576 and in this transmission, SNP A12918 (purple asterisk) is acquired. Subsequently patient 212 transmits the
577 strain without A12918 to patient 374. In scenario (ii), when patient 212 arrives on Ward A, there are already
578 two strains that differ by a single SNP (A12918) circulating on that ward. “X” and “Y” indicate two separate
579 unknown “missing links” -- either asymptomatic patients or staff. For both scenarios i and ii, the inferred upper
580 bounds for acquisition are identical for patients 374, 396, 351, shown in part c.

581 **SUPPLEMENTAL FIGURE 3C** Patient 277 originates cluster GUY1, arriving from home onto Ward A (PVG),
582 where nosocomial patients 355 and 199 are infected. Nosocomial patient 309 is infected on Ward A, picking
583 up the additional variant TTA28062T. Patient 355 is then transferred to Ward B (AMS), which leads to the
584 infection of nosocomial patient 256 and patient 356. In an independent transmission network, nosocomial
585 patient 434 is infected on Ward C (CAN) after the arrival of patient 551, and in the process acquires SNP
586 T2978C.

587 **SUPPLEMENTAL FIGURE 3D** Patient 71 originates cluster GUY3, arriving from home onto Ward A (IC9),
588 then moving to Ward B (HKG) within three days, where nosocomial patients 229, 295, and 363 are infected.
589 All three of these patients acquire SNP A1678G in the process, so it is most parsimonious that patient 71
590 transmitted to one of these patients, who then transmitted it to at least one of the other two. Several days later,
591 patient 301 is admitted to Ward B, where they are infected, and acquire SNP A24033G in the process.

592

593 **SUPPLEMENTAL TABLE 1** Number of tests performed, number of positive tests, number of new cases,
594 combined number of probable and definite nosocomial cases, and number of community viral sequences
595 submitted to CLIMB, all by date from March 9th to March 31st.

596

597 **SUPPLEMENTAL TABLE 2** Cumulative incidence of HCW IgM and IgG seroconversion by week, beginning
598 on Mar 13th until Jun 12th. Total number sampled (n=228)

599

600 **SUPPLEMENTAL TABLE 3** Genomic sequence of viral isolates from cases. Sequence only included if
601 sequenced successfully with >90% coverage at 8x depth. GISAID accession ID, lineage, haplotype, coverage
602 and N positions for each genomic sequence displayed.

603

604 **SUPPLEMENTAL TABLE 4** For each patient, symptom onset (column B), hospital admission or outpatient
605 encounter date (column C) during which first positive SARS-CoV-2 samples is taken. Sample collection date
606 and time (column D) is given, with time between symptom onset and admission (column E) or
607 admission/encounter and sample collection date (column F). The admission/encounter is categorised (column
608 G) as either 'outpatient', 'A&E' where samples are taken in the emergency room when the patient is not
609 admitted, and 'Inpatient' where the patient is admitted during that encounter. Column H categorises patients
610 as either as per the NHS England and ECDC definitions of nosocomial infection (26). Column I shows whether
611 viral sequence for the isolate was successfully obtained..

612

613 **SUPPLEMENTAL TABLE 5:** Patient ward movements. Every encounter or ward stays in the 14 days prior to
614 the first positive test is given, with start and end date. Each row represents a different encounter or ward stay.
615 Ward stays are arranged by ascending patient number and in chronological order.

616

617 **SUPPLEMENTAL TABLE 6:** Epidemiological clusters with ward of overlaps and patients within the cluster.
618 Clusters must contain at least one probable or nosocomial infection (see Methods). Sorted from largest cluster
619 to smallest.

620

621 **SUPPLEMENTAL TABLE 7:** Epidemiological clusters separated into those that isolates that were not
622 sequenced successfully, genetic haplotypes without genetic similarity to other sequenced individuals, and by

623 haplotypes that form clusters with other cases (GUY1 to GUY7, STH1 to STH5, MKH, PLR)

624

625 **SUPPLEMENTAL TABLE 8:** Final transmission clusters with associated hospital site, ward, ward type, lineage
626 and case numbers. Overall number of each noscomail designation for the clusters is given in column G. Seed
627 haplotype is given, with SNP variants from the seed haplotype also reported. The final three columns show
628 the calculation of the hospital enrichment factor; the number of sequences with the seed haplotype from the
629 sequenced isolates from hospital, the number of community samples with this haplotype submitted to CLIMB,
630 and the enrichment factor which is the ratio of these two numbers.

631

632 **SUPPLEMENTAL TABLE 9:** Data used for Fig 3 -- number of patients on each ward for each cluster, for each
633 ward with a provable transmission.

634

635 **SUPPLEMENTAL TABLE 10:** Lower and Upper bounds for the incubation period (days before onset of
636 symptoms) for specific patients based on inferred transmission networks from Fig 5, Fig S2.

637

638 **SUPPLEMENTAL TABLE 11:** Epidemiological clusters that contribute to combined epi + genetic cluster
639 without community-onset or indeterminate cases are assessed to see whether they could contain non-
640 sequenced cases that may serve as originators to the cluster. Cases are deemed not to represent a potential
641 non-sequenced originator if they are a probable or definite nosocomial case, diagnosed after the start of the
642 cluster, or if they do not share significant genome similarity with other cases in the cluster. Epidemiological
643 cluster information is used from Supplemental Table 7

644

645

646

647 REFERENCES

- 648 1. Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*
649 **579**, 270–273 (2020).
- 650 2. John Hopkins University. COVID-19 map-Johns Hopkins Coronavirus Resource Center. (2020). at
651 <<https://coronavirus.jhu.edu/map.html>>
- 652 3. Birrell, P., Blake, J. & van Leeuwen, E. COVID-19: nowcast and forecast. (2020). at
653 <<https://joshuablake.github.io/public-RTM-reports/20200510.html>>
- 654 4. Coronavirus (COVID-19) in the UK. GOV.uk at <<https://coronavirus.data.gov.uk/healthcare>>
- 655 5. England, N. H. S. NHS England » NHS roadmap to safely bring back routine operations. at
656 <<https://www.england.nhs.uk/2020/05/nhs-roadmap/>>
- 657 6. Rickman, H. M. *et al.* Nosocomial transmission of COVID-19: a retrospective study of 66 hospital-
658 acquired cases in a London teaching hospital. *Clin. Infect. Dis.* (2020). doi:10.1093/cid/ciaa816
- 659 7. Taylor, J. *et al.* Nosocomial COVID-19: experience from a large acute NHS Trust in South-West London.
660 *J. Hosp. Infect.* (2020). doi:10.1016/j.jhin.2020.08.018
- 661 8. Cao, G. *et al.* The potential transmission of SARS-CoV-2 from patients with negative RT-PCR swab
662 tests to others: two related clusters of COVID-19 outbreak. *Jpn. J. Infect. Dis.* (2020).
663 doi:10.7883/yoken.JJID.2020.165
- 664 9. Vanhems, P. Fast nosocomial spread of SARS-CoV2 in a French geriatric unit Lyon Study Group on
665 Covid-19 infection. *Infect. Control Hosp. Epidemiol.* 1–4 (2020). doi:10.1017/ice.2020.99
- 666 10. Ji, H., Liu, L., Huang, T. & Zhu, Y. Nosocomial infections in psychiatric hospitals during the COVID-19
667 outbreak. *Eur J Psychiatry* **34**, 177–179 (2020).
- 668 11. Edelstein, M. *et al.* SARS-CoV-2 infection in London, England: changes to community point prevalence
669 around lockdown time, March-May 2020. *J. Epidemiol. Community Health* (2020). doi:10.1136/jech-
670 2020-214730
- 671 12. Lauer, S. A. *et al.* The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly
672 Reported Confirmed Cases: Estimation and Application. *Ann. Intern. Med.* **172**, 577–582 (2020).
- 673 13. Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology,
674 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*
675 **324**, 782–793 (2020).
- 676 14. Meredith, L. W. *et al.* Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-
677 care associated COVID-19: a prospective genomic surveillance study. *Lancet Infect. Dis.* (2020).

- doi:10.1016/S1473-3099(20)30562-4
15. Lucey, M. *et al.* Whole-genome sequencing to track SARS-CoV-2 transmission in nosocomial outbreaks. *Clin. Infect. Dis.* (2020). doi:10.1093/cid/ciaa1433
16. van Dorp, L. *et al.* Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. *Infect. Genet. Evol.* **83**, 104351 (2020).
17. Duchene, S. *et al.* Temporal signal and the phylodynamic threshold of SARS-CoV-2. *Virus Evol* (2020). doi:10.1093/ve/veaa061
18. Wang, D. *et al.* Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* **323**, 1061–1069 (2020).
19. Carter, B. *et al.* Nosocomial COVID-19 infection: examining the risk of mortality. The COPE-Nosocomial Study (COVID in Older PEople). *J. Hosp. Infect.* **106**, 376–384 (2020).
20. Scientific Advisory Group for Emergencies. Dynamic CO-CIN Report to SAGE and NERVTAG, 1 April 2020. (2020). at <<https://www.gov.uk/government/publications/dynamic-co-cin-report-to-sage-and-nervtag-1-april-2020>>
21. Adam, D. C. *et al.* Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. *Nat. Med.* (2020). doi:10.1038/s41591-020-1092-0
22. Disinfection of environments in healthcare and non-healthcare settings potentially contaminated with SARS-CoV-2. (2020). at <<https://www.ecdc.europa.eu/en/publications-data/disinfection-environments-covid-19>>
23. WHO. Transmission of SARS-CoV-2: implications for infection prevention precautions. at <<https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions>>
24. Houlihan, C. F. *et al.* Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. *Lancet* **396**, e6–e7 (2020).
25. Shields, A. *et al.* SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. *Thorax* (2020). doi:10.1136/thoraxjnl-2020-215414
26. Surveillance definitions for COVID-19. at <<https://www.ecdc.europa.eu/en/covid-19/surveillance/surveillance-definitions>>
27. Nicholls, S. M. *et al.* MAJORA: Continuous integration supporting decentralised sequencing for SARS-CoV-2 genomic surveillance. *Cold Spring Harbor Laboratory* 2020.10.06.328328 (2020). doi:10.1101/2020.10.06.328328
28. McAloon, C. *et al.* Incubation period of COVID-19: a rapid systematic review and meta-analysis of

- 710 observational research. *BMJ Open* **10**, e039652 (2020).
- 711 29. Singanayagam, A. *et al.* Duration of infectiousness and correlation with RT-PCR cycle threshold values
- 712 in cases of COVID-19, England, January to May 2020. *Euro Surveill.* **25**, (2020).
- 713 30. COG-UK Project Hospital-Onset COVID-19 Infections Study - Full Text View - ClinicalTrials.gov. at
- 714 <<https://clinicaltrials.gov/ct2/show/NCT04405934>>
- 715 31. Quick, J. nCoV-2019 sequencing protocol v1 (protocols.io.bbmuik6w).
- 716 doi:10.17504/protocols.io.bbmuik6w
- 717 32. Artic Network. at <<https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html>>
- 718 33. *pangolin*. (Github). at <<https://github.com/cov-lineages/pangolin>>
- 719 34. Seow, J. *et al.* Longitudinal observation and decline of neutralizing antibody responses in the three
- 720 months following SARS-CoV-2 infection in humans. *Nat Microbiol* (2020). doi:10.1038/s41564-020-
- 721 00813-8

722

723

724 APPENDIX

725 Funding acquisition, leadership, supervision, metadata curation, project administration, samples, logistics,
726 Sequencing, analysis, and Software and analysis tools:

727 Dr Thomas R Connor PhD^{33, 34}, and Professor Nicholas J Loman PhD¹⁵.

728

729 Leadership, supervision, sequencing, analysis, funding acquisition, metadata curation, project administration,
730 samples, logistics, and visualisation:

731 Dr Samuel C Robson Ph.D ⁶⁸.

732

733 Leadership, supervision, project administration, visualisation, samples, logistics, metadata curation and
734 software and analysis tools:

735 Dr Tanya Golubchik PhD ²⁷.

736

737 Leadership, supervision, metadata curation, project administration, samples, logistics sequencing and
738 analysis:_____

739 Dr M. Estee Torok FRCP ^{8, 10}.

740

741 Project administration, metadata curation, samples, logistics, sequencing, analysis, and software and
742 analysis tools:_____

743 Dr William L Hamilton PhD ^{8, 10}.

744

745 Leadership, supervision, samples logistics, project administration, funding acquisition sequencing and
746 analysis:

747 Dr David Bonsall PhD ²⁷.

748

749 Leadership and supervision, sequencing, analysis, funding acquisition, visualisation and software and
 750 analysis tools:

751 Dr Ali R Awan PhD 74.

752

753 Leadership and supervision, funding acquisition, sequencing, analysis, metadata curation, samples and
 754 logistics:

755 Dr Sally Corden PhD 33 .

756

757 Leadership supervision, sequencing analysis, samples, logistics, and metadata curation:

758 Professor Ian Goodfellow PhD 11.

759

760 Leadership, supervision, sequencing, analysis, samples, logistics, and Project administration:

761 Professor Darren L Smith PhD 60, 61.

762

763 Project administration, metadata curation, samples, logistics, sequencing and analysis:

764 Dr Martin D Curran PhD 14, and Dr Surendra Parmar PhD 14.

765

766 Samples, logistics, metadata curation, project administration sequencing and analysis:

767 Dr James G Shepherd MBChB MRCP 21.

768

769 Sequencing, analysis, project administration, metadata curation and software and analysis tools:

770 Dr Matthew D Parker PhD 38 and Dr Dinesh Aggarwal MRCP 1, 2, 3.

771

772 Leadership, supervision, funding acquisition, samples, logistics, and metadata curation:

773 Dr Catherine Moore³³ .

774

775 Leadership, supervision, metadata curation, samples, logistics, sequencing and analysis:

776 Dr Derek J Fairley PhD 6, 88, Professor Matthew W Loose PhD 54, and Joanne Watkins MSc 33.

777

778 Metadata curation, sequencing, analysis, leadership, supervision and software and analysis tools:

779 Dr Matthew Bull PhD³³ , and Dr Sam Nicholls PhD 15 .

780

781 Leadership, supervision, visualisation, sequencing, analysis and software and analysis tools:

782 Professor David M Aanensen PhD 1, 30.

783

784 Sequencing, analysis, samples, logistics, metadata curation, and visualisation:

785 Dr Sharon Glaysher 70 .

786

787 Metadata curation, sequencing, analysis, visualisation, software and analysis tools:

788 Dr Matthew Bashton PhD 60, and Dr Nicole Pacchiarini PhD 33.

789

790 Sequencing, analysis, visualisation, metadata curation, and software and analysis tools:

791 Dr Anthony P Underwood PhD 1, 30.

792 _____

793 Funding acquisition, leadership, supervision and project administration:

794 Dr Thushan I de Silva PhD 38, and Dr Dennis Wang PhD 38.

795

796 Project administration, samples, logistics, leadership and supervision:

797 Dr Monique Andersson PhD 28 , Professor Anoop J Chauhan 70, Dr Mariateresa de Cesare PhD26, Dr

798 Catherine Ludden 1,3 , and Dr Tabitha W Mahungu FRCPATH 91.

799

800 Sequencing, analysis, project administration and metadata curation:

801 Dr Rebecca Dewar PhD 20, and Martin P McHugh MSc20.

802

803 Samples, logistics, metadata curation and project administration:

804 Dr Natasha G Jesudason MBChB MRCP FRCPATH 21, Dr Kathy K Li MBChB FRCPATH 21, Dr Rajiv N

805 Shah BMBS MRCP MSc 21, and Dr Yusri Taha MD, PhD 66.

806

807 Leadership, supervision, funding acquisition and metadata curation:

808 Dr Kate E Templeton PhD 20.

809

810 Leadership, supervision, funding acquisition, sequencing and analysis:

811 Dr Simon Cottrell PhD 33, Dr Justin O'Grady PhD 51, Professor Andrew Rambaut DPhil 19, and Professor

812 Colin P Smith PhD93.

813

814 Leadership, supervision, metadata curation , sequencing and analysis:

815 Professor Matthew T.G. Holden PhD 87, and Professor Emma C Thomson PhD/FRCP 21.

816

817 Leadership, supervision, samples, logistics and metadata curation:

818 Dr Samuel Moses MD 81, 82.

819

820 Sequencing, analysis, leadership, supervision, samples and logistics:

821 Dr Meera Chand 7, Dr Chrystala Constantinidou PhD 71, Professor Alistair C Darby PhD 46, Professor

822 Julian A Hiscox PhD 46, Professor Steve Paterson PhD 46, and Dr Meera Unnikrishnan PhD 71.

823

824 Sequencing, analysis, leadership and supervision and software and analysis tools:

825 Dr Andrew J Page PhD 51, and Dr Erik M Volz PhD96.

826

827 Samples, logistics, sequencing, analysis and metadata curation:

828 Dr Charlotte J Houldcroft PhD 8, Dr Aminu S Jahun PhD 11, Dr James P McKenna PhD 88, Dr Luke W

829 Meredith PhD 11, Dr Andrew Nelson PhD 61, Sarojini Pandey MSc 72, and Dr Gregory R Young PhD

830 60.

831

832 Sequencing, analysis, metadata curation, and software and analysis tools:

833 Dr Anna Price PhD34, Dr Sara Rey PhD 33, Dr Sunando Roy PhD 41, Dr Ben Temperton Ph.D 49, and

834 Matthew Wyles 38.

835

836 Sequencing, analysis, metadata curation and visualisation:

837 Stefan Rooke MSc19, and Dr Sharif Shaaban PhD87.

838

839 Visualisation, sequencing, analysis and software and analysis tools:

840 Dr Helen Adams PhD 35, Dr Yann Bourgeois Ph.D 69, Dr Katie F Loveson Ph.D 68, Áine O'Toole MSc19,
841 and Richard Stark MSc 71.

842

843 Project administration, leadership and supervision:

844 Dr Ewan M Harrison PhD 1, 3, David Heyburn 33, and Professor Sharon J Peacock 2, 3

845

846 Project administration and funding acquisition:

847 Dr David Buck PhD26 , and Michaela John BSc Hons 36

848

849 Sequencing, analysis and project administration:

850 Dorota Jamroz 1, and Dr Joshua Quick PhD 15

851

852 Samples, logistics, and project administration:

853 Dr Rahul Batra MD78, Katherine L Bellis BSc (Hons) 1, 3, Beth Blane BSc 3 , Sophia T Girgis MSc 3, Dr

854 Angie Green PhD 26, Anita Justice MSc 28 , Dr Mark Kristiansen PhD 41 , and Dr Rachel J Williams

855 PhD 41.

856

857 Project administration, software and analysis tools:

858 Radoslaw Poplawski BSc 15.

859

860 Project administration and visualisation:

861 Dr Garry P Scarlett Ph.D69.

862

863 Leadership, supervision, and funding acquisition:

864 Professor John A Todd PhD 26 , Dr Christophe Fraser PhD 27, Professor Judith Breuer MD 40,41,
865 Professor Sergi Castellano PhD 41, Dr Stephen L Michell PhD 49, Professor Dimitris Gramatopoulos
866 PhD, FRCPATH73, and Dr Jonathan Edgeworth PhD, FRCPATH 78.

867

868 Leadership, supervision and metadata curation:

869 Dr Gemma L Kay PhD 51.

870

871 Leadership, supervision, sequencing and analysis:

872 Dr Ana da Silva Filipe PhD 21 , Dr Aaron R Jeffries PhD 49, Dr Sascha Ott PhD 71, Professor Oliver Pybus
873 24 , Professor David L Robertson PhD 21, Dr David A Simpson PhD 6 , and Dr Chris Williams MB
874 BS33.

875

876 Samples, logistics, leadership and supervision:

877 Dr Cressida Auckland FRCPATH 50, Dr John Boyes MBChB83, Dr Samir Dervisevic FRCPATH52 , Professor
878 Sian Ellard FRCPATH49, 50 , Dr Sonia Goncalves1, Dr Emma J Meader FRCPATH 51, Dr Peter Muir
879 PhD2, Dr Husam Osman PhD 95, Reenesh Prakash MPH52, Dr Venkat Sivaprakasam PhD18, and Dr
880 Ian B Vipond PhD2.

881

882 Leadership, supervision and visualisation

883 Dr Jane AH Masoli MBChB 49, 50.

884

885 Sequencing, analysis and metadata curation

886 Dr Nabil-Fareed Alikhan PhD 51, Matthew Carlile BSc 54, Dr Noel Craine DPhil 33, Dr Sam T Haldenby PhD
 887 46, Dr Nadine Holmes PhD 54, Professor Ronan A Lyons MD 37, Dr Christopher Moore PhD 54,
 888 Malorie Perry MSc 33 , Dr Ben Warne MRCP80, and Dr Thomas Williams MD 19.

889

890 Samples, logistics and metadata curation:

891 Dr Lisa Berry PhD 72, Dr Andrew Bosworth PhD 95 ,Dr Julianne Rose Brown PhD40, Sharon Campbell
 892 MSc 67, Dr Anna Casey PhD 17, Dr Gemma Clark PhD 56, Jennifer Collins BSc 66, Dr Alison
 893 Cox PhD 43, 44 , Thomas Davis MSc 84, Gary Eltringham BSc 66, Dr Cariad Evans 38, 39 , Dr Clive
 894 Graham MD 64, Dr Fenella Halstead PhD 18, Dr Kathryn Ann Harris PhD 40, Dr Christopher Holmes
 895 PhD 58, Stephanie Hutchings 2 , Professor Miren Iturriza-Gomara PhD 46 , Dr Kate Johnson 38, 39,
 896 Katie Jones MSc 72, Dr Alexander J Keeley MRCP 38, Dr Bridget A Knight PhD 49, 50 , Cherian Koshy
 897 MSc, CSci, FIBMS 90, Steven Liggett 63 , Hannah Lowe MSc 81 , Dr Anita O Lucaci PhD 46 , Dr
 898 Jessica Lynch PhD MBChB 25, 29 , Dr Patrick C McClure PhD 55 , Dr Nathan Moore MBChB 31 ,
 899 Matilde Mori BSc 25, 29, 32 , Dr David G Partridge FRCP, FRCPath 38, 39 , Pinglawathee Madona 43,
 900 44 , Hannah M Pymont MSc 2 , Dr Paul Anthony Randell MBBCh 43, 44 , Dr Mohammad Raza 38, 39 ,
 901 Felicity Ryan MSc 81 , Dr Robert Shaw FRCPath 28, Dr Tim J Sloan PhD 57 , and Emma Swindells
 902 BSc 65 .

903

904 Sequencing, analysis, Samples and logistics:

905 Alexander Adams BSc 33, Dr Hibo Asad PhD 33, Alec Birchley MSc 33 , Tony Thomas Brooks BSc (Hons)
 906 41, Dr Giselda Bucca PhD 93, Ethan Butcher 70, Dr Sarah L Caddy PhD 13, Dr Laura G Caller PhD 2,
 907 3, 12 , Yasmin Chaudhry BSc 11, Jason Coombes BSc (HONS) 33, Michelle Cronin 33, Patricia L Dyal
 908 MPhil 41, Johnathan M Evans MSc 33, Laia Fina 33, Bree Gatica-Wilcox MPhil 33, Dr Iliana Georgana
 909 PhD 11, Lauren Gilbert A-Levels 33 , Lee Graham BSc 33, Danielle C Groves BA 38, Grant Hall BSc 11,
 910 Ember Hilvers MPH33 , Dr Myra Hosmillo PhD 11, Hannah Jones 33, Sophie Jones MSc 33, Fahad A
 911 Khokhar BSc 13 , Sara Kumziene-Summerhayes MSc 33, George MacIntyre-Cockett BSc 26, Dr
 912 Rocio T Martinez Nunez PhD 94 , Dr Caoimhe McKerr PhD 33 , Dr Claire McMurray PhD 15, Dr Richard
 913 Myers 7, Yasmin Nicole Panchbhaya BSc 41 , Malte L Pinckert MPhil 11 , Amy Plimmer 33 , Dr Joanne
 914 Stockton PhD 15 , Sarah Taylor 33 , Dr Alicia Thornton 7 , Amy Trebes MSc 26 , Alexander J Trotter

915 MRes 51 ,Helena Jane Tutill BSc 41 ,Charlotte A Williams BSc 41 , Anna Yakovleva BSc 11 and Dr
916 Wen C Yew PhD 62.

917

918

919 Sequencing, analysis and software and analysis tools:

920 Dr Mohammad T Alam PhD 71 , Dr Laura Baxter PhD 71, Olivia Boyd MSc 96 , Dr Fabricia F. Nascimento
921 PhD 96, Timothy M Freeman MPhil 38, Lily Geidelberg MSc 96, Dr Joseph Hughes PhD 21, David
922 Jorgensen MSc 96, Dr Benjamin B Lindsey MRCP 38, Dr Richard J Orton PhD 21 , Dr Manon
923 Ragonnet-Cronin PhD 96 Joel Southgate MSc 33, 34, and Dr Sreenu Vattipally PhD 21.

924

925 Samples, logistics and software and analysis tools:

926 Dr Igor Starinskij MSc MRCP 23.

927

928 Visualisation and software and analysis tools:

929 Dr Joshua B Singer PhD 21 , Dr Khalil Abudahab PhD 1, 30, Leonardo de Oliveira Martins PhD51 , Dr Thanh
930 Le-Viet PhD 51 ,Mirko Menegazzo 30 ,Ben EW Taylor Meng 1, 30, and Dr Corin A Yeats PhD 30.

931

932 Project Administration:

933 Sophie Palmer 3, Carol M Churcher 3 , Dr Alisha Davies 33, Elen De Lacy MSc 33, Fatima Downing 33,
934 Sue Edwards 33 , Dr Nikki Smith PhD 38 , Dr Francisc Coll PhD97 , Dr Nazreen F Hadjirin PhD3
935 and Dr Frances Bolt PhD 44, 45 .

936

937 Leadership and supervision:

938 Dr. Alex Alderton 1, Dr Matt Berriman 1, Ian G Charles 51, Dr Nicholas Cortes MBChB 31 ,Dr Tanya Curran
939 PhD 88 , Prof John Danesh 1, Dr Sahar Eldirdiri MBBS, MSC FRCPATH 84, Dr Ngozi Elumogo FRCPATH

940 52, Prof Andrew Hattersley FRS 49, 50, Professor Alison Holmes MD 44, 45, Dr Robin Howe 33, Dr
 941 Rachel Jones 33 , Anita Kenyon MSc 84, Prof Robert A Kingsley PhD 51, Professor Dominic
 942 Kwiatkowski 1, 9, Dr Cordelia Langford1, Dr Jenifer Mason MBBS 48, Dr Alison E Mather PhD 51, Lizzie
 943 Meadows MA 51, Dr Sian Morgan FRCPATH 36, Dr James Price PhD 44, 45, Trevor I Robinson MSc 48
 944 , Dr Giri Shankar 33 , John Wain 51, and Dr Mark A Webber PhD51 .

945

946 Metadata curation:

947 Dr Declan T Bradley PhD 5, 6 ,Dr Michael R Chapman PhD 1, 3, 4 , Dr Derrick Crooke 28 , Dr David Eyre
 948 PhD 28, Professor Martyn Guest PhD34 , Huw Gulliver 34 , Dr Sarah Hoosdally 28 , Dr Christine
 949 Kitchen PhD 34 , Dr Ian Merrick PhD 34, Siddharth Mookerjee MPH 44, 45 , Robert Munn BSc 34 ,
 950 Professor Timothy Peto PhD28, Will Potter 52, Dr Dheeraj K Sethi MBBS 52, Wendy Smith 56 ,Dr Luke
 951 B Snell MB BS 75, 94 , Dr Rachael Stanley PhD 52 , Claire Stuart 52 and Dr Elizabeth Wastenge MD
 952 20.

953

954 Sequencing and analysis:

955 Dr Erwan Acheson PhD 6 , Safiah Afifi BSc 36 , Dr Elias Allara MD PhD 2, 3 , Dr Roberto Amato 1, Dr
 956 Adrienn Angyal PhD38, Dr Elihu Aranday-Cortes PhD/DVM21 , Cristina Ariani 1, Jordan Ashworth 19,
 957 Dr Stephen Attwood 24, Alp Aydin MSci 51 , David J Baker BEng 51 , Dr Carlos E Balcazar PhD 19,
 958 Angela Beckett MSc 68 Robert Beer BSc 36 , Dr Gilberto Betancor PhD76, Emma
 959 Betteridge 1 , Dr David Bibby 7 , Dr Daniel Bradshaw 7 , Catherine Bresner BSc(Hons) 34, Dr
 960 Hannah E Bridgewater PhD 71 , Alice Broos BSc (Hons) 21 , Dr Rebecca Brown PhD 38 , Dr Paul E
 961 Brown PhD 71, Dr Kirstyn Brunner PhD 22 , Dr Stephen N Carmichael PhD 21 , Jeffrey K. J. Cheng
 962 MSc 71, Dr Rachel Colquhoun DPhil 19 , Dr Gavin Dabrera 7 , Dr Johnny Debebe PhD 54, Eleanor
 963 Drury 1, Dr Louis du Plessis 24 , Richard Eccles MSc 46, Dr Nicholas Ellaby 7, Audrey Farbos MSc 49,
 964 Ben Farr 1 ,Dr Jacqueline Findlay PhD 41 , Chloe L Fisher MSc 74, Leysa Marie Forrest MSc 41, Dr
 965 Sarah Francois 24, Lucy R. Frost BSc 71, William Fuller BSc 34 , Dr Eileen Gallagher 7 , Dr Michael D
 966 Gallagher PhD19 , Matthew Gemmell MSc 46, Dr Rachel AJ Gilroy PhD 51, Scott Goodwin 1, Dr Luke R
 967 Green PhD 38 ,Dr Richard Gregory PhD 46 ,Dr Natalie Groves 7 ,Dr James W Harrison PhD 49,
 968 Hassan Hartman 7 , Dr Andrew R Hesketh PhD93,Verity Hill 19, Dr Jonathan Hubb 7 ,Dr Margaret

969 Hughes PhD46 ,Dr David K Jackson 1 ,Dr Ben Jackson PhD 19 ,Dr Keith James 1 ,Natasha Johnson
 970 BSc (Hons)21 ,Ian Johnston 1, Jon-Paul Keatley 1, Dr Moritz Kraemer 24, Dr Angie Lackenby 7, Dr
 971 Mara Lawniczak 1 , Dr David Lee 7, Rich Livett 1, Stephanie Lo 1, Daniel Mair BSc (Hons) 21, Joshua
 972 Maksimovic FD sport science 36, Nikos Manesis 7 ,Dr Robin Manley Ph.D 49, Dr Carmen Manso 7 ,Dr
 973 Angela Marchbank BSc 34 ,Dr Inigo Martincorena 1 ,Dr Tamy Mbisa 7, Kathryn McCluggage MSC
 974 36,Dr JT McCrone PhD 19, Shahjahan Miah 7 , Michelle L Michelsen BSc 49 , Dr Mari Morgan PhD 33,
 975 Dr Gaia Nebbia PhD, FRCPath 78,Charlotte Nelson MSc 46 ,Jenna Nichols BSc (Hons) 21 ,Dr Paola
 976 Niola PhD 41 ,Dr Kyriaki Nomikou PhD21 ,Steve Palmer 1 , Dr. Naomi Park 1, Dr Yasmin A Parr PhD21
 977 ,Dr Paul J Parsons PhD 38 , Vineet Patel 7 ,Dr. Minal Patel 1 ,Clare Pearson MSc 2, 1 ,Dr Steven Platt
 978 7 ,Christoph Puethe 1, Dr. Mike Quail 1,Dr JaynaRaghwan 24 , Dr Lucille Rainbow PhD 46 ,Shavanthi
 979 Rajatileka 1 ,Dr Mary Ramsay 7 ,Dr Paola C Resende Silva PhD 41, 42, Steven Rudder 51, Dr Chris
 980 Ruis 3 ,Dr Christine M Sambles PhD 49 ,Dr Fei Sang PhD 54 ,Dr Ulf Schaefer7 ,Dr Emily Scher PhD 19
 981 ,Dr. Carol Scott 1 ,Lesley Shirley 1, Adrian W Signell BSc 76 ,John Sillitoe 1 ,Christen Smith 1 ,Dr
 982 Katherine L Smollett PhD 21 ,Karla Spellman FD 36 ,Thomas D Stanton BSc 19 ,Dr David J Studholme
 983 PhD 49 ,Ms Grace Taylor-Joyce BSc 71 ,Dr Ana P Tedim PhD 51 ,Dr Thomas Thompson PhD6 ,Dr
 984 Nicholas M Thomson PhD 51 ,Scott Thurston1 ,Lily Tong PhD 21 ,Gerry Tonkin-Hill 1, Rachel M Tucker
 985 MSc 38 , Dr Edith E Vamos PhD 4,Dr Tetyana Vasylyeva24 , Joanna Warwick-Dugdale BSc 49 , Danni
 986 Weldon 1 ,Dr Mark Whitehead PhD 46 ,Dr David Williams 7,Dr Kathleen A Williamson PhD19,Harry D
 987 Wilson BSc 76,Trudy Workman HNC 34 ,Dr Muhammad Yasir PhD 51, Dr Xiaoyu Yu PhD 19, and Dr
 988 Alex Zarebski 24.

989

990 Samples and logistics:

991 Dr Evelien M Adriaenssens PhD 51, Dr Shazaad S Y Ahmad MSc 2, 47 , Adela Alcolea-Medina MPharm 59,
 992 77 ,Dr John Allan PhD60, Dr Patawee Asamaphan PhD21, Laura Atkinson MSc 40, Paul Baker MD 63,
 993 Professor Jonathan Ball PhD 55, Dr Edward Barton MD64, Dr. Mathew A Beale1, Dr. Charlotte Beaver1
 994 , Dr Andrew Beggs PhD16, Dr Andrew Bell PhD51, Duncan J Berger 1, Dr Louise Berry. 56, Claire M
 995 Bewshea MSc 49, Kelly Bicknell 70, Paul Bird 58, Dr Chloe Bishop 7 , Dr Tim Boswell 56, Cassie Breen
 996 BSc48, Dr Sarah K Buddenborg1, Dr Shirelle Burton-Fanning MD 66, Dr Vicki Chalker 7, Dr Joseph G
 997 Chappell PhD 55, Themoula Charalampous MSc 78, 94, Claire Cormie3, Dr Nick Cortes PhD29, 25, Dr
 998 Lindsay J Coupland PhD 52, Angela Cowell MSc48 , Dr Rose K Davidson PhD 53 , Joana Dias MSc3 ,

999 Dr Maria Diaz PhD51 , Thomas Dibling1, Matthew J Dorman1, Dr Nichola Duckworth57, Scott Elliott70,
1000 Sarah Essex63, Karlie Fallon 58 , Theresa Feltwell 8 , Dr Vicki M Fleming PhD 56, Sally Forrest BSc 3,
1001 Luke Foulser1, Maria V Garcia-Casado1, Dr Artemis Gavriil PhD 41, Dr Ryan P George PhD47, Laura
1002 Gifford MSc 33, Harmeet K Gill PhD3, Jane Greenaway MSc65, Luke Griffith Bsc53, Ana Victoria
1003 Gutierrez51, Dr Antony D Hale MBBS85, Dr Tanzina Haque FRCPath, PhD91, Katherine L Harper
1004 MBiol85, Dr Ian Harrison 7 , Dr Judith Heaney PhD89, Thomas Helmer 58, Ellen E Higginson PhD 3 ,
1005 Richard Hopes 2, Dr Hannah C Howson-Wells PhD 56, Dr Adam D Hunter 1, Robert Impey 70, Dr
1006 Dianne Irish-Tavares FRCPath 91, David A Jackson1 , Kathryn A Jackson MSc 46 , Dr Amelia Joseph
1007 56, Leanne Kane 1, Sally Kay 1, Leanne M Kermack MSc 3, Manjinder Khakh 56, Dr Stephen P Kidd
1008 PhD29, 25,31, , Dr Anastasia Kolyva PhD 51, Jack CD Lee BSc 40, Laura Letchford 1 , Nick Levene
1009 MSc79, Dr LisaJ Levett PhD 89, Dr Michelle M Lister PhD 56, Allyson Lloyd 70 , Dr Joshua Loh PhD60 ,
1010 Dr Louissa R Macfarlane-Smith PhD85, Dr Nicholas W Machin MSc 2 , 47, Mailis Maes M.phil3, Dr
1011 Samantha McGuigan 1, Liz McMinn 1, Dr Lamia Mestek-Boukhibar D.Phil 41, Dr Zoltan Molnar PhD 6,
1012 Lynn Monaghan 79, Dr Catrin Moore 27, Plamena Naydenova BSc 3, Alexandra S Neaverson 1, Dr.
1013 Rachel Nelson PhD 1, Marc O Niebel MSc21 , Elaine O'Toole BSc 48 , Debra Padgett BSc 64, Gaurang
1014 Patel 1 , Dr Brendan Al Payne MD 66, Liam Prestwood 1, Dr Veena Raviprakash MD67, Nicola
1015 Reynolds PhD86 Dr Alex Richter PhD 16, Dr Esther Robinson PhD95, Dr Hazel A Rogers1, Dr Aileen
1016 Rowan PhD 96, Garren Scott BSc 64, Dr Divya Shah PhD40, Nicola Sheriff BSc 67, Dr Graciela Sluga
1017 MD - MSc92 , Emily Souster1, Dr. Michael Spencer-Chapman1, Sushmita Sridhar BSc1, 3, Tracey
1018 Swinger 53, Dr Julian Tang58, Professor Graham P Taylor DSc96, Dr Theocharis Tsoleridis PhD55, Dr
1019 Lance Turtle PhD MRCP46, Dr Sarah Walsh 57, Dr Michelle Wantoch PhD 86, Joanne Watts BSc48 ,
1020 Dr Sheila Waugh MD66, Sam Weeks41, Dr Rebecca Williams BMBS 31, Dr Iona Willingham56, Dr
1021 Emma L Wise PhD 25, 29, 31, Victoria Wright BSc 54, Dr Sarah Wyllie 70 , and Jamie Young BSc 3.

1022

1023 Software and analysis tools

1024 Amy Gaskin MSc33, Dr Will Rowe PhD 15, and Dr Igor Siveroni PhD96.

1025

1026 Visualisation:

1027 Dr Robert Johnson PhD 96.

1028

1029 1 Wellcome Sanger Institute, 2 Public Health England, 3 University of Cambridge, 4 Health Data Research
 1030 UK, Cambridge, 5 Public Health Agency, Northern Ireland, 6 Queen's University Belfast 7 Public Health
 1031 England Colindale, 8 Department of Medicine, University of Cambridge, 9 University of Oxford, 10
 1032 Departments of Infectious Diseases and Microbiology, Cambridge University Hospitals NHS Foundation
 1033 Trust; Cambridge, UK, 11 Division of Virology, Department of Pathology, University of Cambridge, 12
 1034 The Francis Crick Institute, 13 Cambridge Institute for Therapeutic Immunology and Infectious Disease,
 1035 Department of Medicine, 14 Public Health England, Clinical Microbiology and Public Health Laboratory,
 1036 Cambridge, UK, 15 Institute of Microbiology and Infection, University of Birmingham, 16 University of
 1037 Birmingham, 17 Queen Elizabeth Hospital, 18 Heartlands Hospital, 19 University of Edinburgh, 20 NHS
 1038 Lothian, 21 MRC-University of Glasgow Centre for Virus Research, 22 Institute of Biodiversity, Animal
 1039 Health & Comparative Medicine, University of Glasgow, 23 West of Scotland Specialist Virology Centre,
 1040 24 Dept Zoology, University of Oxford, 25 University of Surrey, 26 Wellcome Centre for Human
 1041 Genetics, Nuffield Department of Medicine, University of Oxford, 27 Big Data Institute, Nuffield
 1042 Department of Medicine, University of Oxford, 28 Oxford University Hospitals NHS Foundation Trust, 29
 1043 Basingstoke Hospital, 30 Centre for Genomic Pathogen Surveillance, University of Oxford, 31
 1044 Hampshire Hospitals NHS Foundation Trust, 32 University of Southampton, 33 Public Health Wales
 1045 NHS Trust, 34 Cardiff University, 35 Betsi Cadwaladr University Health Board, 36 Cardiff and Vale
 1046 University Health Board, 37 Swansea University, 38 University of Sheffield, 39 Sheffield Teaching
 1047 Hospitals, 40 Great Ormond Street NHS Foundation Trust, 41 University College London, 42 Oswaldo
 1048 Cruz Institute, Rio de Janeiro 43 North West London Pathology, 44 Imperial College Healthcare NHS
 1049 Trust, 45 NIHR Health Protection Research Unit in HCAI and AMR, Imperial College London, 46
 1050 University of Liverpool, 47 Manchester University NHS Foundation Trust, 48 Liverpool Clinical
 1051 Laboratories, 49 University of Exeter, 50 Royal Devon and Exeter NHS Foundation Trust, 51 Quadram
 1052 Institute Bioscience, University of East Anglia, 52 Norfolk and Norwich University Hospital, 53 University
 1053 of East Anglia, 54 Deep Seq, School of Life Sciences, Queens Medical Centre, University of
 1054 Nottingham, 55 Virology, School of Life Sciences, Queens Medical Centre, University of Nottingham, 56
 1055 Clinical Microbiology Department, Queens Medical Centre, 57 PathLinks, Northern Lincolnshire & Goole
 1056 NHS Foundation Trust, 58 Clinical Microbiology, University Hospitals of Leicester NHS Trust, 59
 1057 Viapath, 60 Hub for Biotechnology in the Built Environment, Northumbria University, 61 NU-OMICS
 1058 Northumbria University, 62 Northumbria University, 63 South Tees Hospitals NHS Foundation Trust, 64

1059 North Cumbria Integrated Care NHS Foundation Trust, 65 North Tees and Hartlepool NHS Foundation
 1060 Trust, 66 Newcastle Hospitals NHS Foundation Trust, 67 County Durham and Darlington NHS
 1061 Foundation Trust, 68 Centre for Enzyme Innovation, University of Portsmouth, 69 School of Biological
 1062 Sciences, University of Portsmouth, 70 Portsmouth Hospitals NHS Trust, 71 University of Warwick, 72
 1063 University Hospitals Coventry and Warwickshire, 73 Warwick Medical School and Institute of Precision
 1064 Diagnostics, Pathology, UHCW NHS Trust, 74 Genomics Innovation Unit, Guy's and St. Thomas' NHS
 1065 Foundation Trust, 75 Centre for Clinical Infection & Diagnostics Research, St. Thomas' Hospital and
 1066 Kings College London, 76 Department of Infectious Diseases, King's College London, 77 Guy's and St.
 1067 Thomas' Hospitals NHS Foundation Trust, 78 Centre for Clinical Infection and Diagnostics Research,
 1068 Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, 79 Princess
 1069 Alexandra Hospital Microbiology Dept. , 80 Cambridge University Hospitals NHS Foundation Trust, 81
 1070 East Kent Hospitals University NHS Foundation Trust, 82 University of Kent, 83 Gloucestershire
 1071 Hospitals NHS Foundation Trust, 84 Department of Microbiology, Kettering General Hospital, 85
 1072 National Infection Service, PHE and Leeds Teaching Hospitals Trust, 86 Cambridge Stem Cell Institute,
 1073 University of Cambridge, 87 Public Health Scotland, 88 Belfast Health & Social Care Trust, 89 Health
 1074 Services Laboratories, 90 Barking, Havering and Redbridge University Hospitals NHS Trust, 91 Royal
 1075 Free NHS Trust, 92 Maidstone and Tunbridge Wells NHS Trust, 93 University of Brighton, 94 Kings
 1076 College London, 95 PHE Heartlands, 96 Imperial College London, 97 Department of Infection Biology,
 1077 London School of Hygiene and Tropical Medicine.

TABLE 1

	Overall			Community		Indeterminate		Probable nosocomial		Definite nosocomial	
Cases (n)	574			462	80%	22	4%	27	5%	63	11%
In-hospital mortality	114	20%		78	17%	5	23%	9	33%	23	37%
Sex											
Female	251	44%		203	44%	6	27%	12	44%	30	48%
Male	323	56%		259	56%	16	73%	15	56%	33	52%
Median age (IQR)	61 (48-76)			58 (45-73)		73 (61-77)		73 (65-81)		73 (61-81)	
Ethnicity											
Asian	27	5%		23	5%	0	0%	1	4%	3	5%
Black	157	27%		141	31%	4	18%	4	15%	8	13%
Other	36	6%		33	7%	1	5%	0	0%	2	3%
White	230	40%		170	37%	6	27%	15	56%	39	62%
Mixed	5	1%		4	1%	1	5%	0	0%	0	0%
Unknown	119	21%		91	20%	10	45%	7	26%	11	17%
Known	455	79%		371	80%	12	55%	20	74%	52	83%
BAME	225	49%		201	54%	6	50%	5	25%	13	25%
Pregnant	13	2%		13	3%	0	0%	0		0	0%
Smoker											
Never	449	78%		373	80%	17	77%	15	56%	44	70%
Current	26	5%		17	4%	2	9%	3	11%	4	6%
Ex	99	17%		72	16%	3	14%	9	33%	15	24%
Alcohol excess	17	3%		12	3%	1	5%	1	4%	3	5%
Charlson score (IQR)	3 (1-5)			2 (0-5)		4 (3-6)		5 (4-6)		5 (4-6)	
Solid tumor	71	12%		45	10%	6	27%	4	15%	16	25%
Localised	53	9%		36	8%	3	14%	2	7%	12	19%
Metastatic	18	3%		9	2%	3	14%	2	7%	4	6%
Haematological malignancy	14	2%		4	1%	2	9%	2	7%	6	10%
Lymphoma	7	1%		1	0%	2	9%	1	4%	3	5%
Leukaemia	7	1%		3	1%	0	0%	1	4%	3	5%
Renal impairment	110	19%		84	18%	3	14%	9	33%	14	22%
Mild	49	9%		33	7%	3	14%	4	15%	9	14%
Moderate	7	1%		5	1%	0	0%	1	4%	1	2%
Severe	54	9%		46	10%	0	0%	4	15%	4	6%
Chronic liver disease	15	3%		11	2%	0	0%	0	0%	4	6%
Dementia	50	9%		29	6%	3	14%	4	15%	14	22%
Immunosuppression	35	6%		24	5%	0	0%	2	7%	9	14%
HIV/AIDS	2	0%		2	0%	0	0%	0	0%	0	0%
Peptic ulcer disease	9	2%		5	1%	0	0%	0	0%	4	6%
Diabetes mellitus	168	29%		134	29%	5	23%	10	37%	19	30%
End organ damage	38	7%		27	6%	2	9%	5	19%	4	6%
Connective tissue disease	13	2%		10	2%	1	5%	0		2	3%
Hypertension	257	45%		199	43%	9	41%	17	63%	32	51%
TIA/CVA	45	8%		28	6%	1	5%	1	4%	15	24%
Congestive cardiac failure	28	5%		13	3%	0	0%	5	19%	10	16%
Peripheral vascular disease	13	2%		6	1%	1	5%	3	11%	3	5%
Myocardial infarction	19	3%		11	2%	1	5%	3	11%	4	6%
COPD	46	8%		29	6%	2	9%	4	15%	11	17%

Figure 1

Figure 2

Figure 3

Figure 4

Figure 3